세계 천식 치료제 시장 : 규모, 점유율, 동향분석 보고서 -약품 클래스별, 제품별, 투여경로별, 지역별, 부문별 예측(2024-2030년)

Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti- inflammatory, Bronchodilators), By Product (Inhalers, Nebulizers), By Routeof Administration (Oral, Inhaled), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,221,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,602,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,366,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

천식 치료제 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 천식 치료제 시장 규모는 2030년까지 379억 1,000만 달러에 이를 전망이며, 2024년부터 2030년까지 복합 연간 성장률(CAGR) 5.3%로 확대될 것으로 예측됩니다.

천식 유병률 증가와 중증 천식을 치료하기 위한 장기 치료 옵션으로서의 생물학적 제제의 채용이 결합되어 이 시장에 유리한 성장 기회를 제공할 것으로 기대됩니다. World Allergy Journal이 발표한 통계에 따르면, 2014년 5월 천식으로 고통받는 환자는 약 3억명에 이르고, 건강에 해로운 식생활이나 앉기 쉬운 라이프스타일에 기울이는 사람이 많기 때문에 그 수는 급증 예상됩니다.

또한 예측기간 동안 싱레어, 애드에어 등 주요 브랜드 의약품의 특허가 해지되면서 제네릭 의약품 경쟁이 치열해지고 앞으로 몇 년동안 천식 치료제 시장의 성장에 부정적인 영향을 미칠 것입니다. 반대로, 생물학적 제제의 도입은 천식 치료제 부문 시장 점유율 확대로 이어지며, 예측 기간 동안 계속될 것으로 예상됩니다.

중증 천식 치료에서 기존의 약물 처방 패턴과는 달리 개인화된 의료 접근법에 대한 수요가 증가하고 있다는 것은 미래의 천식 치료제 시장의 출현을 뒷받침할 것으로 예상됩니다. 또한 센서 기술과 내장 무선 통신 시스템을 갖춘 가압식 정량 흡입기, 스마트 흡입기 등의 기술적으로 첨단 제품의 개발은 향후 7년간 천식 치료제 시장의 성장을 더욱 촉진할 것으로 예상 .

천식 치료제 시장 보고서 하이라이트

• 항염증제 부류는 심각한 천식 상태를 목표로 하는 경제적인 혁신적인 생물학적 제제의 도입으로 예측 기간 동안 급성장할 것으로 예상됩니다. 그 밖의 특전으로서 생물학적 제제나 단클론항체에 의해 초래되는 이익에 대한 인식이 높아지고 있어 향후 수년간 시장의 확대가 전망됩니다.
• 드라이 파우더 흡입기(DPI)는 다른 흡입기보다 임상 효율이 높기 때문에 이러한 장치의 채용이 증가하고 있기 때문에 가장 빠르게 성장하는 부문이 될 것으로 예상됩니다. 건조 분말 흡입기(DPI)는 다른 흡입기보다 임상 효율이 높기 때문에 채용이 증가하고 있습니다. 이러한 이점은 채용률을 급상승시키고 시장 침투율 상승에 기여하고 있습니다.
• 천식 치료제로 흡입 합제와 같은 대체 치료법을 선택하는 개인 수 증가는 이 시장에 미래 성장 기회를 가져올 것으로 예상됩니다.
• 천식 치료 시장에서 사업을 전개하는 주요 기업은 AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boecsing Merck&Co, Inc. 등이 있습니다.
• 시장 경쟁 우위를 확보하기 위해 시장 리더는 기술적으로 첨단 장비와 새로운 개량형 생물 제제의 도입에 주력하고 있습니다. 천식치료제 분야에서는 개발단계에 있는 신규 분자가 100 가까이 있고, 제조업체 각사는 맞춤형 치료의 개발에 주력하고 있기 때문에 파이프라인이 매우 충실합니다. 앞서 언급한 요인은 전체적으로 가까운 미래에 업계의 성장을 강화할 것입니다.
• 예를 들어, Teva Pharmaceutical Industries Ltd.의 Cinquil, Roche의 Lebrikizumab(Phase III), AB Science의 Mastinib(Phase II/ III), GlaxoSmithKline Plc의 Bosatria(Phase III)와 같은 의약 분자는 임상 연구 시험 중 개발 단계입니다. 에 있습니다. 예측기간 중에 상업이용이 가능하게 되면 이 수직통합형 항암제에 탄력이 생길 것으로 기대됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 천식 치료제 시장 : 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 천식 치료제 시장 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 천식 치료제 시장 : 약제 클래스의 추정,동향 분석

• 약제 클래스 시장 점유율(2023년,2030년)
• 부문 대시보드
• 약제 클래스별 세계 천식 치료제 시장 전망
• 시장 규모, 예측 및 동향 분석(2018년-2030년)

제5장 천식 치료제 시장 : 제품의 추정,동향 분석

• 제품 시장 점유율(2023년,2030년)
• 부문 대시보드
• 제품별 세계 천식 치료제 시장 전망
• 시장 규모, 예측 및 동향 분석(2018년-2030년)

제6장 천식 치료제 시장 : 투여 경로의 추정,동향 분석

• 투여 경로 시장 점유율(2023년,2030년)
• 부문 대시보드
• 투여 경로별 세계 천식 치료제 시장 전망
• 시장 규모, 예측 및 동향 분석(2018년-2030년)

제7장 천식 치료제 시장 :지역의 추정,동향 분석

• 지역 시장 점유율 분석(2023년,2030년)
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석(2018년-2030년)
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업별 최근의 동향과 영향 분석
• 회사/경쟁의 분류
• 벤더 상황
  • Teva Pharmaceutical Industries Ltd
  • GSK plc
  • Merck &Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Koninklijke Philips NV
  • BD
  • Covis Pharma

BJH

영문 목차

영문목차

Asthma Therapeutics Market Growth & Trends:

The global asthma therapeutics market size is expected to reach USD 37.91 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of asthma coupled with the adoption of biologics as a long-term treatment option to treat the severe form of asthma is expected to offer this market with lucrative growth opportunities. According to the statistics published by the World Allergy Journal, in May 2014, patients suffering from asthma registered around 300 million and the number is expected to soar due to a large number of individuals inclining towards unhealthy dietary habits and sedentary lifestyles.

In addition, patent expiration of branded drugs, such as Singulair, Advair and other major drugs during the forecast period has led to a stiff generic competition, which will negatively impact the asthma therapeutics market growth in the coming years. On the contrary, the introduction of biologics is accruing towards the increasing market share of the asthma therapeutics segment, and is anticipated to continue during the forecast period.

The enhanced demand for personalized medicine approach as opposed to the conventional medication prescription pattern for treatment of severe asthma is anticipated to aid the emergence of asthma therapeutics market in the future. In addition, development of technologically advanced products, such as pressurized metered dose inhalers and smart inhalers, equipped with sensor technology and inbuilt wireless communication system is further expected to propel the asthma therapeutics market growth in the next seven years.

Asthma Therapeutics Market Report Highlights:

• The anti-inflammatory drug class is expected to exhibit rapid growth of over the forecast period owing to the introduction of affordable and innovative biologics targeting the severe asthma condition. In addition, the awareness gained pertaining to the benefits rendered by the biologics and monoclonal antibodies is anticipated to exhibit an upward shift in the market expansion in the coming years.
• The dry powder inhalers (DPIs) are expected to be the fastest growing segment due to the increasing adoption of these devices because of their high clinical efficiency than other inhalers. They are able to deliver both, small and large-sized drug components and dispense specialty engineered molecules. These related merits have spiked the adoption rates thereby contributing towards the risen market penetration.
• Rising number of individuals opting for alternative treatment options, such as inhaled fixed-dose combination drugs for asthma medication is anticipated to serve this market with future growth opportunities.
• Some of the key players operating in the asthma therapeutics market include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck& Co., Inc.
• Market leaders are focusing on the introduction of technologically advanced devices and novel, improved biologics to gain a competitive advantage. The asthma therapeutics segment has a very strong pipeline as there are almost 100 novel molecules that are in the development phase and manufacturers are focusing on the development of personalized medication. The aforementioned factors collectively strengthen the industry growth in the near future.
• For instance, drug molecules, such as Cinquil by Teva Pharmaceutical Industries Ltd., Lebrikizumab by Roche (Phase III), Mastinib by AB Science (Phase II/III), and Bosatria by GlaxoSmithKline Plc (Phase III), are in the development stage undergoing clinical research trials. Their commercial availability during the forecast period is expected to provide a boost to this vertical.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Product
  • 1.2.3. Route of Administration
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for Primary Interviews in North America
    • 1.4.5.2. Data for Primary Interviews in Europe
    • 1.4.5.3. Data for Primary Interviews in Asia Pacific
    • 1.4.5.4. Data for Primary Interviews in Latin America
    • 1.4.5.5. Data for Primary Interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Product outlook
  • 2.2.3. Rout of administration outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Asthma Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of asthma
    • 3.2.1.2. Emergence of novel biologics
    • 3.2.1.3. Rising awareness programs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Patent expiration of branded drugs
    • 3.2.2.2. Regulatory challenges
• 3.3. Asthma Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Asthma Therapeutics Market by Drug Class Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Anti- inflammatory
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Bronchodilators
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.3. Combination Therapy
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Asthma Therapeutics Market: Product Estimates & Trend Analysis

• 5.1. Product Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Asthma Therapeutics Market by Product Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Inhalers
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.1.2. Dry Powder
    • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.1.3. Metered Dose
    • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.1.4. Soft Mist
    • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Nebulizers
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Asthma Therapeutics Market by Route of Administration Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Oral
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Inhaled
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.3. Others
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Asthma Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.6. Europe
  • 7.6.1. Germany
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.2. UK
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.4. South Korea
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.5. Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Teva Pharmaceutical Industries Ltd
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. GSK plc
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck & Co., Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. F. Hoffmann-La Roche Ltd
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. AstraZeneca
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Boehringer Ingelheim International GmbH
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Sanofi
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Koninklijke Philips N.V.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. BD
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Covis Pharma
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives

관련자료